BuTrans 15 microgram/hour transdermal patches
- Name:
BuTrans 15 microgram/hour transdermal patches
- Company:
Mundipharma Pharmaceuticals Limited - Formerly Napp Laboratories
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 11/02/19
(Click to Download)Click on this link to Download PDF directly
Mundipharma Pharmaceuticals Limited - Formerly Napp Laboratories
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 11 February 2019 PIL
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 6 - what the product looks like and pack contents
Updated on 11 February 2019 SmPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Addition of details of child resistant packaging
Updated on 2 February 2017 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The following has been replaced with (added text in red)
Benzodiazepines: This combination can potentiate respiratory depression of central origin, with risk of death in case of overdose (see section 4.4).
Benzodiazepines: This combination can potentiate respiratory depression of central origin(see section 4.4).
Section 4.6
The following has been changed (text in red has been added)
Prolonged use Long term administration of buprenorphine during the last three months of pregnancy can result in neonatal opioid may cause a withdrawal syndrome. in the neonate.
Section 4.8
(Psychiartic disorders) Affect lability has been changed from liability. Libido decreased has been changed from Decreased Libido.
(Nervous system disorders) Seizures has been added. Abnormal co-ordination has been changed to Co-ordination abnormal.
Renal and urinary disorders - Urinary incontinence has been added. Urinary hesitation has been added. Micturtion disorder has been removed.
General disorders and administration site conditions - Drug withdrawal syndrome neonatal has been added.
Updated on 2 February 2017 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 26 January 2017 PIL
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - possible side effects
Updated on 26 January 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 4 May 2016 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 18 April 2016 PIL
Reasons for updating
- New PIL for new product